Key facts
- It has raised $85.0M across 1 recorded rounds; the latest was Later Stage VC ($85.0M) in Apr 2024.
- Notable investors include Insight Partners (New York), OrbiMed, Innovation Endeavors, The Invus Group, Novartis Venture Fund — 12 tracked in total.
- Averna Therapeutics has filed 1 Form D with the SEC, most recently Mar 2026 ($85.0M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Averna Therapeutics
Funding rounds
1 roundsAbout Averna Therapeutics
Developer of genomic medicine designed to transform the treatment of a broad range of diseases. The company develops medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions, and can be delivered using non-viral delivery platforms to treat a broad range of diseases, enabling healthcare organizations to improve product quality, reduce testing costs, and accelerate the test automation and engineering expertise.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2022
- Employees
- 48
- Website
- avernatx.com/
- Ownership
- Privately Held (backing)
Averna Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Averna Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Averna Therapeutics in its N-PORT filings yet. We sweep new filings monthly.